Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Down 5.58%
As of Tuesday, October 13, Assembly Biosciences, Inc.’s ASMB share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Down 5.27%
As of Tuesday, September 15, Assembly Biosciences, Inc.’s ASMB share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Down 6.48%
As of Thursday, September 10, Assembly Biosciences, Inc.’s ASMB share price has dipped by 6.48%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Up 5.33%
As of Tuesday, August 18, Assembly Biosciences, Inc.’s ASMB share price has surged by 5.33%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Down 5.01%
As of Monday, August 17, Assembly Biosciences, Inc.’s ASMB share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ASMB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $463.6 | $237.5 | 37% |
|
| Shares Out (Mil) | 18.9 | 53.9 | 30% |
|
| Institutional Ownership | 93.2% | 93.1% | 62% |
|
| Float (Mil) | 9.2 | 41.4 | 18% |
|
| Beta | 1.09 | 0.95 | 65% |
|
| Avg Daily Volume (000s) | 262 | 628 | 48% |
|
| Price Change (52-week) |
(15.1%) | 49.0% | 40% |
|
| Growth | ASMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (1.8%) | 12.4% | 14% |
|
| Net Income (5yr) | 37.1% | (10.2%) | 89% |
|
| EPS (5yr) | 51.8% | 15.7% | 93 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.1%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.495) | ($0.118) | ($2.574) | |
| Month Ago EPS | ($0.495) | ($0.118) | ($2.574) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.505) | $0.140 | ($2.105) | |
| Year/Year Chg | 141.5% | (78.4%) | 257.7% | |
| Financials | ASMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $75 | $37 | 24% |
|
| Net Income (TTM) (Mil) | $0 | ($44) | 39% |
|
| EPS (TTM) | ($0.003) | ($1.600) | 39% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $2 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $353 | $174 | 31% |
|
| Valuation | ASMB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.48 | 2.27 | 41% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ASMB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 15.0% | 66.9% | 14% |
|
| Net Margin | (0.1%) | (75.3%) | 31% |
|
| ROA | 0.0% | (47.7%) | 38% |
|
| ROE | 0.0% | (55.0%) | 35% |
|
| Liabilities to Assets | 7.6% | 29.4% | 4% |
|
| F-Score | 4 | 2 | 33% |
|
Assembly Biosciences, Inc. did not pass any screens on 10/12/2026.
